The phase III ALTA-1L trial evaluating Alunbrig (brigatinib) versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer who had not received a prior ALK inhibitor demonstrated reduced risk of disease progression or death.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
